Aventus Health has introduced a new test, named COVID-19 Variant Test, to precisely detect known SARS-CoV-2 variants as well as identify new variants.

The test was created by integrating the company’s next-generation sequencing (NGS) technology with a lab-made assay that jointly breaks down the sequence of base pairs forming the genetic structure of the different SARS-CoV-2 strains.

This testing approach offers results that can be used to study, monitor and understand Covid-19 variants and their effect on public health.

Apart from the variant test, Aventus has a suite of Covid-19 testing services.

The company will now incorporate reflex testing to NGS into all of its reverse transcription-polymerase chain reaction (RT-PCR) patient tests that deliver a positive result in a bid to detect known and emerging variants.

Aventus CEO Oliver Dawoud said: “At the onset of the pandemic, Aventus released one of the most accurate Covid-19 RT-PCR tests in the market and went on to make Covid-19 testing widely available through our partnerships.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“To complete our wide array of services, we were able to utilise our state-of-the-art technology to bring to market SARS-CoV-2 variant testing. This is a breakthrough in healthcare that will greatly aid the general public in better understanding the different strains of Covid-19.”

Aventus medical director Michelle Taylor added that variant testing is complex as it needs genomic sequencing processes, which involve expensive technology and diagnostic capabilities.

Taylor added: “The instruments Aventus uses are manufactured for the highest sensitivity genetic sequencing capabilities on the market.

“They are critical to our mission of helping healthcare providers leverage innovations in genomics and diagnostics to deliver affordable and effective personalised and precision medicine.”

The Aventus Health portfolio includes integrated healthcare service companies and clinical care facilities.

It offers a platform for a variety of cost-effective and advanced solutions, including laboratory diagnostics, specialised pharmacies and interventional experts.